Free Trial

Daniel Clark Analyst Performance

Vice President - Equity Research at Leerink Partners

Daniel Clark is a stock analyst at Leerink Partners in the medical sector, covering 2 publicly traded companies. Over the past year, Daniel Clark has issued 5 stock ratings, including and buy recommendations. While full access to Daniel Clark's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Daniel Clark's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
5 Last 0 Years
Buy Recommendations
100.00% 4 Buy Ratings
Companies Covered
2 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy100.0%4 ratings
Hold0.0%0 ratings
Sell0.0%0 ratings

the majority (100.0%) have been Buy recommendations.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NYSE
50.0% of companies on NYSE
1 company
NASDAQ
50.0% of companies on NASDAQ
1 company

Daniel Clark, an analyst at Leerink Partners, currently covers 2 companies listed on NYSE and NASDAQ, with the majority traded on NYSE.

Coverage Focus

Sector IconSectorPercentage
Medical
2 companies
100.0%

Daniel Clark of Leerink Partners specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - OUTP/HM CRE
1 company
50.0%
MED INSTRUMENTS
1 company
50.0%

Daniel Clark's Ratings History at Leerink Partners

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2/24/2026Boost Price Target$25.77$30.00Outperform
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
11/3/2025Set Price Target$722.94$785.00
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
7/17/2025Upgrade$14.51$18.00Outperform
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
7/17/2025Boost Price Target$519.61$600.00Outperform
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
6/11/2025Boost Price Target$522.26$580.00Outperform